Print

Pharmaceutical Company Dompe Launches REP0112, a Trial to Assess the Efficacy and Safety of Reparixin in Autologous Islet Cell Transplantation  
9/26/2013 10:09:32 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MONTEREY, Calif.--(BUSINESS WIRE)--Italian biopharmaceutical company Dompé today announced the launch of REP0112, a randomized double-blind multicenter Phase II/III trial to assess the efficacy and safety of Reparixin in autologous islet cell transplantation, a procedure where, unlike transplantation from a donor, pancreatic cells are taken from the patient's own pancreas and surgically removed for pancreatic pathology. Launch of the trial was announced at the 14th World Congress of the International Pancreas and Islet Transplant Association (IPITA 2013) in Monterey, California. “Dompé is committed to identifying treatment solutions for rare, often orphan, diseases. For this reason we are particularly proud of the launch of this Phase II/III trial in the US, a step that brings us closer to providing patients with another effective and safe treatment that satisfies medical needs that are still unmet,” said Eugenio Aringhieri, CEO, Dompé. “The trial we are announcing today and Reparixin, one of the drugs developed by our company, produced at our bio-technology sites and supplied globally, are a testament to our commitment in the industry. This also marks a milestone in our expansion into the US, a country where we recently established a Group subsidiary.”

Help employers find you! Check out all the jobs and post your resume.

//-->